350 related articles for article (PubMed ID: 24993360)
21. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
22. Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.
Gu C; Ye T; Wells RA
Leuk Res; 2006 Nov; 30(11):1447-51. PubMed ID: 16704876
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9.
Secker KA; Keppeler H; Duerr-Stoerzer S; Schmid H; Schneidawind D; Hentrich T; Schulze-Hentrich JM; Mankel B; Fend F; Schneidawind C
Oncogene; 2019 Nov; 38(46):7181-7195. PubMed ID: 31417187
[TBL] [Abstract][Full Text] [Related]
24. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
Barry ER; Corry GN; Rasmussen TP
Expert Opin Ther Targets; 2010 Apr; 14(4):405-18. PubMed ID: 20230194
[TBL] [Abstract][Full Text] [Related]
25. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
26. Reconstructing the disease model and epigenetic networks for MLL-AF4 leukemia.
Zeisig BB; Cheung N; Yeung J; So CW
Cancer Cell; 2008 Nov; 14(5):345-7. PubMed ID: 18977321
[TBL] [Abstract][Full Text] [Related]
27. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
[TBL] [Abstract][Full Text] [Related]
28. Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L.
Stein EM; Tallman MS
Curr Opin Hematol; 2015 Mar; 22(2):92-6. PubMed ID: 25635757
[TBL] [Abstract][Full Text] [Related]
29. The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells.
Lai YS; Chen JY; Tsai HJ; Chen TY; Hung WC
Blood Cancer J; 2015 May; 5(5):e313. PubMed ID: 25978433
[TBL] [Abstract][Full Text] [Related]
30. Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1.
Chaib H; Nebbioso A; Prebet T; Castellano R; Garbit S; Restouin A; Vey N; Altucci L; Collette Y
Leukemia; 2012 Apr; 26(4):662-74. PubMed ID: 21979880
[TBL] [Abstract][Full Text] [Related]
31. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
[TBL] [Abstract][Full Text] [Related]
32. Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression.
Dou L; Zheng D; Li J; Li Y; Gao L; Wang L; Yu L
Oncogene; 2012 Jan; 31(4):507-17. PubMed ID: 21706045
[TBL] [Abstract][Full Text] [Related]
33. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
34. Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1.
Kimura S; Kuramoto K; Homan J; Naruoka H; Ego T; Nogawa M; Sugahara S; Naito H
Anticancer Res; 2012 Mar; 32(3):795-8. PubMed ID: 22399596
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of
Lonetti A; Indio V; Laginestra MA; Tarantino G; Chiarini F; Astolfi A; Bertuccio SN; Martelli AM; Locatelli F; Pession A; Masetti R
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698374
[TBL] [Abstract][Full Text] [Related]
36. Discovery, Structure-Activity Relationship and In Vitro Anticancer Activity of Small-Molecule Inhibitors of the Protein-Protein Interactions between AF9/ENL and AF4 or DOT1L.
Li X; Wu X; Nie S; Zhao J; Yao Y; Wu F; Mishra CB; Ashraf-Uz-Zaman M; Moku BK; Song Y
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958457
[TBL] [Abstract][Full Text] [Related]
37. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
38. Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors.
Cao H; Cheng Y; You L; Qian J; Qian W
Mol Med Rep; 2013 Jun; 7(6):1838-44. PubMed ID: 23620163
[TBL] [Abstract][Full Text] [Related]
39. Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression.
Zhang M; Aguilar A; Xu S; Huang L; Chinnaswamy K; Sleger T; Wang B; Gross S; Nicolay BN; Ronseaux S; Harvey K; Wang Y; McEachern D; Kirchhoff PD; Liu Z; Stuckey J; Tron AE; Liu T; Wang S
J Med Chem; 2021 Jul; 64(14):10333-10349. PubMed ID: 34196551
[TBL] [Abstract][Full Text] [Related]
40. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
Tafuri A; Lemoli RM; Chen R; Gulati SC; Clarkson BD; Andreeff M
Leukemia; 1994 May; 8(5):749-57. PubMed ID: 7514244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
